COVID-19 Outbreak-Global Chronic Kidney Disease (CKD) Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
- 70613
- 22-Dec
- Pharmaceutical
- 124
- MRR
-
Report Details
Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure. The Chronic Kidney Disease (CKD) Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform. In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Chronic Kidney Disease (CKD) Drugs industry. Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain. In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy. The Chronic Kidney Disease (CKD) Drugs market can be split based on product types, major applications, and important countries as follows: Key players in the global Chronic Kidney Disease (CKD) Drugs market covered in Chapter 12: AstraZeneca plc GlaxoSmithKline plc. FibroGen Inc Johnson & Johnson Amgen Inc. Teva Pharmaceutical Industries Ltd. Hoffmann-La Roche Ltd. Pfizer, Inc. Allergan plc. Sanofi S.A. Keryx Biopharmaceuticals, Inc. AbbVie, Inc. Kissei Pharmaceutical Co., Ltd In Chapter 4 and 14.1, on the basis of types, the Chronic Kidney Disease (CKD) Drugs market from 2015 to 2025 is primarily split into: Calcium Channel Blockers Antihypertensive Anemia Treatment Drugs Antihyperlipidemic Erythropoiesis-stimulating Agents (ESAs) Swelling Treatment Drugs Beta Blockers Diuretics Angiotensin-II Receptor Blockers ACE Inhibitors Other Drug Classes In Chapter 5 and 14.2, on the basis of applications, the Chronic Kidney Disease (CKD) Drugs market from 2015 to 2025 covers: Specialty Clinics Hospitals Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14: North America (Covered in Chapter 7 and 14) United States Canada Mexico Europe (Covered in Chapter 8 and 14) Germany UK France Italy Spain Russia Others Asia-Pacific (Covered in Chapter 9 and 14) China Japan South Korea Australia India Southeast Asia Others Middle East and Africa (Covered in Chapter 10 and 14) Saudi Arabia UAE Egypt Nigeria South Africa Others South America (Covered in Chapter 11 and 14) Brazil Argentina Columbia Chile Others Years considered for this report: Historical Years: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Period: 2020-2025
-
Table Of Content
Table of Content 1 Chronic Kidney Disease (CKD) Drugs Introduction and Market Overview 1.1 Objectives of the Study 1.2 Overview of Chronic Kidney Disease (CKD) Drugs 1.3 Scope of The Study 1.3.1 Key Market Segments 1.3.2 Players Covered 1.3.3 COVID-19's impact on the Chronic Kidney Disease (CKD) Drugs industry 1.4 Methodology of The Study 1.5 Research Data Source 2 Executive Summary
-
Inquiry Before Buying
-
Request Sample